Leishmaniasis: drugs in the clinic, resistance and new developments.
about
Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasisComparative analysis of the omics technologies used to study antimonial, amphotericin B, and pentamidine resistance in leishmaniaPentavalent antimonials: new perspectives for old drugsResveratrol is active against Leishmania amazonensis: in vitro effect of its association with Amphotericin BUnresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites.CYP5122A1, a novel cytochrome P450 is essential for survival of Leishmania donovaniGene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensisRole of efflux pumps and intracellular thiols in natural antimony resistant isolates of Leishmania donovaniDifferent Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct MechanismsPhospholipid and sphingolipid metabolism in Leishmania.Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.Antimony transport mechanisms in resistant leishmania parasites.Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance.A Computational Methodology to Overcome the Challenges Associated With the Search for Specific Enzyme Targets to Develop Drugs Against Leishmania major.Biochemical and genetic analysis of methylenetetrahydrofolate reductase in Leishmania metabolism and virulence.Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.Systemic therapy of New World cutaneous leishmaniasis: A case report and review article.N-(4-Chloro-phen-yl)ethanimidamide.Stealth Amphotericin B nanoparticles for oral drug delivery: In vitro optimization.Andrographolide nanoparticles in leishmaniasis: characterization and in vitro evaluations.Antiparasitic effects of gold nanoparticles with microwave radiation on promastigots and amastigotes of Leishmania major.Protein kinases as drug targets in trypanosomes and Leishmania.In silico work flow for scaffold hopping in LeishmaniaApplying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis.Modulation of Leishmania ABC protein gene expression through life stages and among drug-resistant parasites.Cameroonian medicinal plants: pharmacology and derived natural productsEfficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials.Leishmania is not prone to develop resistance to tamoxifen.Leishmanicidal Effect of Synthetic trans-Resveratrol Analogs.Leishmania tarentolae: purification and characterization of tubulin and its suitability for antileishmanial drug screeningFormulation and optimization of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of Amphotericin B.Aromatic diamidines as antiparasitic agents.Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasisMulticomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activityLibrary of Seleno-Compounds as Novel Agents against Leishmania Species.Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis.Cos-Seq for high-throughput identification of drug target and resistance mechanisms in the protozoan parasite Leishmania.A new ABC half-transporter in Leishmania major is involved in resistance to antimony.Prodrugs for the treatment of neglected diseases.The Brown Alga Stypopodium zonale (Dictyotaceae): A Potential Source of Anti-Leishmania Drugs.
P2860
Q24674183-4D780C32-1385-4D91-B790-E5A74F968A6FQ27009505-7839228E-5542-45EB-B485-9E67ED94208EQ28253055-4A6B9CFF-4E80-433F-A7A9-13E21BBF0DF3Q28395466-DE4126F0-D3E8-407D-B677-6A36047AB042Q28468760-69CA3384-B16A-405C-BFF3-1E8DF7AF5CECQ28477209-53A56017-DAD9-49E5-8D10-A8841AC57E88Q28478242-EA3F62B4-240B-4278-ABB0-97BFA961A8EEQ28533525-8AEA4627-512D-4266-A444-F52B9FC6A94BQ28554770-99E242A6-DDF4-4606-974D-CE506F024053Q33625755-B3E589AC-EF2C-47FE-8FC1-2F1D592C18D1Q33637372-934B032F-01C1-4761-AC6E-C04CF06425FDQ33659312-A9E7654A-3FA2-4427-892D-FB99EBD37495Q33797823-76D2983F-98A8-4899-9356-A1E94774A64FQ33797941-908AB950-E0E3-4F72-8952-F10BABB8B55AQ34000109-5E86014F-416D-46CD-BCE9-16CDD10314EFQ34024861-CF4FA5BC-49F4-4207-97D6-BF2A4C54F376Q34028355-27DC9020-50C4-4DA3-B34F-51ADAD55B2C9Q34319840-C19BB47F-F43D-4B96-A8DC-BB1A8F6B0C7DQ34482076-AC76D5C0-723A-49F1-87A1-F6AC8C8A12ABQ34501958-557B796C-31A4-4857-BED0-A52582234EF0Q34545589-96D4E556-309B-416A-AD96-CE4BDAD14CADQ34578463-70E180FA-7D49-4F8D-BC58-9BCB1B41F9C8Q34584775-2E5344AB-2F56-4AFF-8273-F4A7DA03F2D0Q35029988-4ADCF1CA-7523-44AD-9563-9CCAFB9514E0Q35075211-4457B5D7-B891-433E-BD7C-9481424D0581Q35155222-EAD3BA54-FD6B-4F2A-8276-25E4002AEB81Q35640976-95FFC0C7-8D5E-49C3-A70E-F7CC8056761BQ35801671-DD49230D-BEB7-4A96-A79B-0EACEF43449AQ35827365-F0A69771-6932-46F6-A7E0-B54946B53E92Q36003229-8FCB0D00-EF4C-4E29-9EA7-672B2BEA636FQ36194875-AF18ABF4-EA61-46E2-98BF-78836B785215Q36210897-75C13A80-2787-4DB6-9D83-07758863C1DEQ36232091-0B206639-0DB0-4A24-8CC4-AEE8A2B9293DQ36263511-336B27CD-9DF9-49AF-9236-DD4E565762D6Q36315604-1A442E85-3224-4EB5-B0C4-2D2DB8039CA3Q36951420-5ED53677-CE37-48C2-B368-0EE4BC9DA49AQ36957213-7055E935-2C25-4C6C-B995-EE86310EA43BQ37036630-3D84AEB4-C16A-4AD0-B8F6-6142E10349F9Q37157236-0AFF2841-73CE-4DF4-9C85-3D734427AE83Q37290911-A398EBA4-7B24-4DB4-8DF4-BF5DC0C80F07
P2860
Leishmaniasis: drugs in the clinic, resistance and new developments.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Leishmaniasis: drugs in the clinic, resistance and new developments.
@ast
Leishmaniasis: drugs in the clinic, resistance and new developments.
@en
type
label
Leishmaniasis: drugs in the clinic, resistance and new developments.
@ast
Leishmaniasis: drugs in the clinic, resistance and new developments.
@en
prefLabel
Leishmaniasis: drugs in the clinic, resistance and new developments.
@ast
Leishmaniasis: drugs in the clinic, resistance and new developments.
@en
P1476
Leishmaniasis: drugs in the clinic, resistance and new developments
@en
P2093
Barbara Papadopoulou
Jolyne Drummelsmith
P304
P356
10.1016/J.DRUP.2004.07.002
P577
2004-08-01T00:00:00Z